Sorry, Santa: AbbVie Shows ‘Naughty’ Can Be Profitably Nice (For Some)
AbbVie’s “patent thicket” strategy and aggressive drug pricing tactics have made it a prominent example of pharma finagling. But the company isn’t the only beneficiary.
Author archive
AbbVie’s “patent thicket” strategy and aggressive drug pricing tactics have made it a prominent example of pharma finagling. But the company isn’t the only beneficiary.
It was an unexpected message: invest in Israeli health technology today in order to reap the benefits tomorrow of innovations spurred by the Israel-Gaza conflict.
A lawsuit spurred by a series of STAT stories accuses UnitedHealth of deploying an algorithm with a known high error rate, as investigative journalism flourishes.
It’s open enrollment season for Medicare, but star ratings for Medicare Advantage plans, meant to promote consumerism and value, can contain misleading information.
Grappling with what ChatGPT and generative AI will mean for health and medicine? The president of the National Academy of Medicine is both “excited” and “scared.”
The patient safety movement has succeeded in getting the president to consider their policy proposals, but if hospitals are hesitant, implementation will be difficulty
Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday September 28 at 1pm PST 4pm EST are futurist Jeff Goldsmith: author & ponderer of odd juxtapositions Kim Bellard (@kimbbellard); and patient safety expertContinue reading…
Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday August 31 at 1pm PST 4pm EST are the small but mighty pairing of Kim Bellard (@kimbbellard); and patient safety expert and all aroundContinue reading…
It’s hard to read the latest report on Medicare ACOs without feeling a tinge of sadness about what could ave been.
This is the last of the classics that THCB will run to celebrate our 20th birthday. And we are finally tackling the most important of questions. Is what we call this thingContinue reading…